KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 5,104 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the sale, the chief executive officer now owns 278,855 shares of the company's stock, valued at approximately $2,738,356.10. This represents a 1.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
KalVista Pharmaceuticals Stock Performance
Shares of KALV stock traded down $0.61 on Friday, hitting $10.03. The company's stock had a trading volume of 447,802 shares, compared to its average volume of 309,626. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $15.50. The company has a market capitalization of $495.68 million, a PE ratio of -2.76 and a beta of 0.85. The stock's 50 day moving average is $8.84 and its 200-day moving average is $10.43.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.01. On average, research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.
Hedge Funds Weigh In On KalVista Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Aquatic Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals during the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC boosted its position in shares of KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 5,502 shares in the last quarter. Legal & General Group Plc grew its stake in shares of KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 1,494 shares during the period. China Universal Asset Management Co. Ltd. increased its position in KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company's stock valued at $96,000 after buying an additional 3,328 shares in the last quarter. Finally, Martin Worley Group bought a new stake in KalVista Pharmaceuticals in the 4th quarter valued at about $86,000.
Wall Street Analyst Weigh In
KALV has been the topic of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. TD Cowen began coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating and a $30.00 target price for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Finally, Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $23.80.
Check Out Our Latest Report on KALV
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Featured Articles
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
